Nike Inc vs Tilray Brands Inc — how do they compare? Nike Inc trades at $37.14 (market cap $56.52B), while Tilray Brands Inc trades at $4.21 (market cap $591.60M). The key difference: Nike Inc is far larger — about 95.5× Tilray Brands Inc's market cap, and Nike Inc pays a 4.3% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| NKE | TLRY | |
|---|---|---|
Market Cap | $56.52B | $591.60M |
Volume | 8,887,180 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $74.57 | $21.00 |
52-Week Low | $37.35 | $3.88 |
Enterprise Value | $58.53B | $758.73M |
Dividend Yield | 4.3% | — |
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $37.35, down 2.73% amid bearish technical signals and recent earnings volatility. The stock shows strong profitability metrics with 42.91% gross margins and 22.14% ROE, but faces revenue pressure with FY2025 sales declining to $46.31B. Analyst consensus remains positive with a $49.81 price target, though technical indicators signal caution with 17 sell signals versus 3 buy signals.
Nike's investment case balances strong brand equity and recent earnings beats against China market challenges and inventory pressures. The stock offers 33% upside to consensus targets but requires successful execution of the 'Win Now' turnaround strategy to overcome near-term headwinds in key markets.
TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.
TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →